York Pharma announces sales collaboration with Sinclair Pharma

22 December 2008, Milton Keynes, UK: York Pharma plc (YRK:L), the AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology, announces today that it has entered into a commercial collaboration with Sinclair Pharma in the UK. Under the terms of the agreement, each company will co-promote selected products to dermatologists and selected GP's.

York Pharma's sales force will co-market Sinclair's Atopiclair product for atopic dermatitis; Sinclair Pharma's sales force will co-promote certain York Pharma products, including the anti-acne product Zindaclin and the emollient QV. The agreement comes into force in January 2009 and relates specifically to the UK market.

In addition to the agreement announced today, discussions between the two companies are ongoing to evaluate the expansion of the co-marketing relationship into other key European territories.

Terry Sadler, Chief Executive of York Pharma, added:

"We're delighted to be working with Sinclair Pharma, initially in the UK market, where York has a number of approved products which can be promoted to both GP's and dermatologists. We believe this collaboration will help optimise the value of York Pharma's portfolio and accelerate our sales growth ahead of the anticipated commercialisation of Abasol in the UK in 2009."

Dr Michael Flynn, CEO of Sinclair Pharma said:

"This agreement effectively doubles the number of specialist salespersons promoting the two companies' dermatology products in the UK.  For Sinclair this is particularly important for the promotion to dermatologists of our reimbursed product Atopiclair for the treatment of atopic dermatitis. We are exploring similar synergies with York in other European countries."